Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 196,540 shares of CRSP, which is worth approximately $9.23 Million. The most recent transaction as insider was on Nov 11, 2024, when has been sold 30,000 shares (Common Shares) at a price of $55.85 per share, resulting in proceeds of $1,675,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 197K

11.67% 3M change

49.26% 12M change

Total Value Held $9.23 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 11 2024	SELL Open market or private sale	$1,675,500 $55.85 p/Share	30,000 Reduced 13.24%	196,540 Common Shares
Oct 14 2024	SELL Open market or private sale	$198,680 $46.28 p/Share	4,293 Reduced 1.86%	226,540 Common Shares
Oct 13 2024	BUY Exercise of conversion of derivative security	-	8,333 Added 3.48%	230,833 Common Shares
Aug 08 2024	SELL Bona fide gift	-	100,000 Reduced 31.01%	222,500 Common Shares
Apr 15 2024	SELL Open market or private sale	$1,177,661 $60.14 p/Share	19,582 Reduced 8.6%	208,122 Common Shares
Apr 15 2024	BUY Exercise of conversion of derivative security	$374,407 $19.12 p/Share	19,582 Added 7.92%	227,704 Common Shares
Mar 15 2024	SELL Open market or private sale	$1,450,200 $72.51 p/Share	20,000 Reduced 8.77%	208,122 Common Shares
Mar 15 2024	BUY Exercise of conversion of derivative security	$382,400 $19.12 p/Share	20,000 Added 8.06%	228,122 Common Shares
Mar 12 2024	SELL Open market or private sale	$341,158 $74.44 p/Share	4,583 Reduced 2.15%	208,122 Common Shares
Mar 11 2024	SELL Open market or private sale	$767,104 $78.26 p/Share	9,802 Reduced 4.59%	203,705 Common Shares
Mar 11 2024	BUY Exercise of conversion of derivative security	-	9,000 Added 4.06%	212,705 Common Shares
Mar 10 2024	BUY Exercise of conversion of derivative security	-	19,250 Added 8.27%	213,507 Common Shares
Feb 20 2024	SELL Open market or private sale	$507,497 $79.67 p/Share	6,370 Reduced 3.18%	194,257 Common Shares
Feb 18 2024	BUY Exercise of conversion of derivative security	-	13,250 Added 6.2%	200,627 Common Shares
Feb 15 2024	SELL Open market or private sale	$1,617,600 $80.88 p/Share	20,000 Reduced 9.64%	187,377 Common Shares
Feb 15 2024	BUY Exercise of conversion of derivative security	$382,400 $19.12 p/Share	20,000 Added 8.8%	207,377 Common Shares
Jan 29 2024	SELL Open market or private sale	$3,040,000 $60.8 p/Share	50,000 Reduced 21.06%	187,377 Common Shares
Jan 29 2024	BUY Exercise of conversion of derivative security	$956,000 $19.12 p/Share	50,000 Added 17.4%	237,377 Common Shares
Jan 16 2024	SELL Open market or private sale	$1,250,000 $62.5 p/Share	20,000 Reduced 9.64%	187,377 Common Shares
Jan 16 2024	BUY Exercise of conversion of derivative security	$382,400 $19.12 p/Share	20,000 Added 8.8%	207,377 Common Shares
May 30 2023	SELL Open market or private sale	$1,628,250 $65.13 p/Share	25,000 Reduced 6.06%	387,377 Common Shares
May 30 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.72%	412,377 Common Shares
Apr 25 2023	SELL Open market or private sale	$1,274,500 $50.98 p/Share	25,000 Reduced 6.06%	387,377 Common Shares
Apr 25 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.72%	412,377 Common Shares
Mar 29 2023	SELL Open market or private sale	$1,114,250 $44.57 p/Share	25,000 Reduced 6.06%	387,377 Common Shares

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director